Flora Sam, MD
Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Cardiovascular Medicine

MD, University of the Witwatersrand



Dr. Sam is the present Director, ad interim, of the Whitaker Cardiovascular Institute. She is an advanced heart failure clinical cardiologist and a physician-scientist. She is a translational researcher and the PI of her NIH funded lab. She is an expert in cardiac myocyte biology and in mechanisms of myocardial remodeling in cardiomyopathy, both in humans and animal models. She is a recognized expert in "heart failure with preserved ejection fraction" (HFpEF) /diastolic heart failure and "heart failure with reduced ejection fraction" (HFrEF)/systolic heart failure and cardiomyopathies.

The Sam lab is focused on three major areas of investigation:
1) Pro-inflammatory and pro-fibrotic mechanisms that mediate cardiac remodeling in heart failure, cardiac hypertrophy and hypertension.
2) Investigating the relationship between matrix markers and heart failure in humans with cardiac amyloid and scleroderma.
3) Investigating cross talk between adipocyte-derived factors, myokines and cardiokines in heart failure.

Member
Boston University
Whitaker Cardiovascular Institute


Graduate Medical Sciences Educator and Mentor (Primary Mentor of Graduate Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences




Mechanistic underpinnings of increased adipose tissue in HFpEF
07/01/2019 - 06/30/2025 (PI)
NIH/National Heart, Lung, and Blood Institute
5R01HL145985-04

Protocol #C1973-204 - A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 over 12 Weeks in Patients with Heart
04/18/2018 - 04/17/2022 (PI)
Ironwood Pharmaceuticals, Inc.


Protocol # EFC15156:A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of SOtagLiflozin on Clinical Outcomes in HemOdynamIcally STable Patients
11/12/2018 - 11/12/2021 (PI)
Sanofi-Aventis, U.S., LLC


Dual ETA/ETB antagonist macitentan inhibits the progression from left ventricular (LV) hypertrophy to heart failure in a murine model of diastolic heart failure
10/15/2014 - 10/14/2019 (PI)
Actelion Pharmaceuticals, Ltd.


Role of Aldosterone and Adiponectin in Inter-Tissue Communication in Diastolic Heart Failure
06/01/2016 - 05/31/2019 (PI)
NIH/National Heart, Lung, and Blood Institute
4R01HL117153-04

Role of Aldosterone and Adiponectin in Inter-Tissue Communication in Diastolic Heart Failure
09/01/2013 - 05/31/2016 (PI)
NIH/National Heart, Lung, and Blood Institute
5R01HL117153-03

Follistatin-Like 1 and the Cardiac Secretome in Human Heart Failure
04/15/2010 - 03/31/2014 (PI)
NIH/National Heart, Lung, and Blood Institute
5R21HL102631-02

The REVIVE Study
06/01/2002 - 07/31/2003 (PI)
Abbott Laboratories

A Placebo Controlled Trial of Bidil Added to Standard Therapy in African-American Patients with Heart Failure
11/01/2001 - 10/30/2002 (PI)
NitroMed Inc


Role of Aldosterone in Cardiac Remodeling
06/01/2005 - 04/30/2010 (PI)
NIH-NHLBI
5 R01 HL079099-03 (A)

Fixed-does isosorbide dinitrate and hydralazine in a mouse left ventricular pressure overload model
02/01/2006 - 01/31/2007 (PI)
Nitromed

Oxidative Stress/AE in Heart Failure
08/01/2000 - 07/31/2005 (PI)
NIH-NHLBI
5 K23 HL004423-05

Aldosterone in Transition from Hypetrophy
07/01/2002 - 06/30/2005 (PI)
American Heart Assoc


Title


Yr Title Project-Sub Proj Pubs
2022 Mechanistic underpinnings of increased adipose tissue in HFpEF 5R01HL145985-04
2021 Mechanistic underpinnings of increased adipose tissue in HFpEF 5R01HL145985-03 1
2020 Mechanistic underpinnings of increased adipose tissue in HFpEF 5R01HL145985-02 1
2019 Mechanistic underpinnings of increased adipose tissue in HFpEF 1R01HL145985-01A1 1
2016 Role of Aldosterone and Adiponectin in Inter-Tissue Communication in Diastolic He 4R01HL117153-04 9
2015 Role of Aldosterone and Adiponectin in Inter-Tissue Communication in Diastolic He 5R01HL117153-03 9
2014 Role of Aldosterone and Adiponectin in Inter-Tissue Communication in Diastolic He 5R01HL117153-02 9
2013 Role of Aldosterone and Adiponectin in Inter-Tissue Communication in Diastolic He 1R01HL117153-01A1 9
2011 Follistatin-like 1 and the cardiac secretome in human heart failure 5R21HL102631-02 8
2011 Novel Insights into the Pathogenesis of Light Chain Cardiac Amyloidosis 5R21HL095891-02 16
Showing 10 of 28 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Yu Z, Chen Y, Miranda O, Qi M, Zhang M, Feng N, Ryan TP, Schloot NC, Chen Y, Sam F, Wang L. Association of Long-Term Body Mass Index Variability With the Development of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction Across Patterns of Weight Change. J Am Heart Assoc. 2025 Sep 16; 14(18):e039976. PMID: 40932106; PMCID: PMC12554408; DOI: 10.1161/JAHA.124.039976;
     
  2. Borlaug BA, Testani JM, Petrie MC, Wang Z, Cunningham J, Adams KF, Amir O, Belohlávek J, Bocchi E, Freitas A, Hominal M, Kadokami T, Merkely B, Miller CA, Nuñez J, Verma S, Yilmaz MB, Oru E, Sam F. Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial. Nat Med. 2025 Nov; 31(11):3853-3861. PMID: 40887551; PMCID: PMC12618225; DOI: 10.1038/s41591-025-03939-6;
     
  3. Saw EL, Werner LD, Cooper HL, Pimental DR, Zamani P, Chirinos JA, Valero-Muñoz M, Sam F. Musclin Counteracts Skeletal Muscle Dysfunction and Exercise Intolerance in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2025 Jun; 18(6):e012350.View Related Profiles. PMID: 40358602; PMCID: PMC12165570; DOI: 10.1161/CIRCHEARTFAILURE.124.012350;
     
  4. Valero-Muñoz M, Saw EL, Cooper H, Pimentel DR, Sam F. White Adipose Tissue in Obesity-Associated HFpEF: Insights From Mice and Humans. JACC Basic Transl Sci. 2025 Aug; 10(8):101262.View Related Profiles. PMID: 40338771; PMCID: PMC12399134; DOI: 10.1016/j.jacbts.2025.02.021;
     
  5. Han S, Yu S, Shi M, Harada M, Ge J, Lin J, Prehn C, Petrera A, Li Y, Sam F, Matullo G, Adamski J, Suhre K, Gieger C, Hauck SM, Herder C, Roden M, Casale FP, Cai N, Peters A, Wang-Sattler R. LEOPARD: missing view completion for multi-timepoint omics data via representation disentanglement and temporal knowledge transfer. Nat Commun. 2025 Apr 06; 16(1):3278. PMID: 40188173; PMCID: PMC11972361; DOI: 10.1038/s41467-025-58314-3;
     
  6. Tham LS, Heerspink HJL, Wang X, Verdino P, Saifan CG, Benson EA, Goldsmith P, Wang Z, Testani JM, Haupt A, Sam F, Cherney DZI. Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial. Nephrol Dial Transplant. 2024 Dec 20; 40(1):109-122. PMID: 38782726; PMCID: PMC11659974; DOI: 10.1093/ndt/gfae112;
     
  7. Valero-Muñoz M, Sam F. Endothelin-1: Is it Time to "Biomark" the Cardiac-Tumor-Treatment Nexus in Breast Cancer? JACC CardioOncol. 2023 Oct; 5(5):701-703. PMID: 37969651; PMCID: PMC10635882; DOI: 10.1016/j.jaccao.2023.05.007;
     
  8. Ferdinand KC, Dunn J, Nicolay C, Sam F, Blue EK, Wang H. Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes. Cardiovasc Diabetol. 2023 Mar 09; 22(1):49. PMID: 36894938; PMCID: PMC9999488; DOI: 10.1186/s12933-023-01775-x;
     
  9. El-Adili F, Lui JK, Najem M, Farina G, Trojanowska M, Sam F, Bujor AM. Correction: Periostin overexpression in scleroderma cardiac tissue and its utility as a marker for disease complications. Arthritis Res Ther. 2023 Jan 23; 25(1):11.View Related Profiles. PMID: 36691037; PMCID: PMC9869504; DOI: 10.1186/s13075-023-02993-0;
     
  10. Saw EL, Werner LD, Zamani P, Chirinos JA, Valero-Muñoz M, Sam F. Skeletal muscle phenotypic switching in heart failure with preserved ejection fraction. Front Cardiovasc Med. 2022; 9:1016452.View Related Profiles. PMID: 36531739; PMCID: PMC9753550; DOI: 10.3389/fcvm.2022.1016452;
     
Showing 10 of 90 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 90 publications over 26 distinct years, with a maximum of 9 publications in 2011 and 2013

YearPublications
19982
19991
20001
20013
20043
20053
20063
20074
20081
20096
20105
20119
20121
20139
20142
20155
20163
20172
20182
20194
20202
20215
20225
20233
20241
20255


2018 Association of University Cardiologists: Elected Member, Association of University Cardiologists (AUC)
2016 Heart Failure Society of America: Fellow of the Heart Failure Society of America (FHFSA)
2011 American Society of Clinical Investigation: Member, American Society of Clinical Investigation (ASCI)
2009 American Heart Association: Fellow of the American Heart Association (FAHA)
2003 American College of Cardiology: Fellow of the American College of Cardiology (FACC)

I serve as a mentor to postgraduate trainees (doctoral and medical students), residents-in-training, post-doctoral fellows, clinical fellows and junior faculty. My role is to assist in the professional advancement that is aligned with the individual's goal as the mentee enters into the next stage of their career, such as academia, pharma, research or clinical medicine.

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

88 E. Newton St Newton Pavilion
Boston MA 02118
Google Map


Sam's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department